CD274 and non-small cell lung carcinoma: Immunotherapy with PD‐1/PD‐L1 antibody drugs have been approved in the U.S. since 2014, and WFO recommend treatment with immunotherapy drugs such as pembrolizumab, or nivolumab and either one alone or combined with chemotherapy for metastatic NSCLC as the first‐line treatment, but chemotherapy was the only regimen available for consideration.